Toggle sidebar
定价
登录
Lilly raises outlook for third time this year as Zepbound sales soar.
礼来(US:LLY)
MarketWatch
·
2026-10-29 19:03
核心观点 - 该药物继续主导美国处方减肥药市场 [1] 市场格局 - 该药物在美国处方减肥药市场中占据主导地位 [1]
Lilly raises outlook for third time this year as Zepbound sales soar. - Reportify